Wegovy is the brand name for semaglutide, manufactured by Novo Nordisk, FDA-approved for chronic weight management (BMI ≥30 or ≥27 with weight-related comorbidity) since 2021. Expanded in 2024 to include cardiovascular risk reduction in adults with overweight/obesity + established CVD.

How much does Wegovy cost?

List price ~$1,349/mo. With NovoCare savings or insurance, often $499-$649/mo. Coverage varies — many plans require step therapy and BMI documentation.

Wegovy — Drug Reference, Dosing, Trials | American Telehealth Review

Name: Wegovy — Drug Reference, Dosing, Trials | American Telehealth Review
Published: 2026-06-01

Wegovy

Brand name for semaglutide 2.4 mg, FDA-approved for chronic weight management and cardiovascular risk reduction in adults with overweight/obesity + established CVD.

By Novo NordiskUpdated 2026-06-01

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-01

Wegovy overview

Brand name for semaglutide 2.4 mg, FDA-approved for chronic weight management and cardiovascular risk reduction in adults with overweight/obesity + established CVD.

Wegovy at a glance

Manufacturer

Novo Nordisk

FDA status

FDA-approved

Clinical research overview
Compare GLP-1 forms
Compounded vs brand
NexLife (Editor's #1)

Wegovy

Wegovy overview

Wegovy at a glance

Related pages